High-flow Nasal Oxygen in Palliative Care: Pilot Study
- Conditions
- Dyspnea
- Interventions
- Device: high-flow nasal cannula oxygen therapy (HNFC)
- Registration Number
- NCT03423888
- Lead Sponsor
- University Hospital, Toulouse
- Brief Summary
In palliative care, the relief of the dyspnea is necessary. Medications for the reduction of dyspnea have side effects. High-flow nasal cannula oxygen therapy (HFNC) is a new way to deliver oxygen. Investigators hypothesize that HNFC is an acceptable technic for the patient with dyspnea in palliative care.
A pilot study with 30 patients will be conducted. Acceptability of HNFC will be studied by the time of use by patients of the HNFC during one week. The effectiveness of HNFC in relieving dyspnea will be studied using Borg scale.
- Detailed Description
Pilot study for acceptability of high flow nasal cannula oxygen therapy in palliative care Population: 30 patients in palliative care (for lung cancer, terminal respiratory failure) who suffer from dyspnea and have oxygen therapy. Patients with curative care are excluded and patients who require non invasive ventilation.
An oral consent is asked.
Primary objective: acceptability of HNFC in patients with dyspnea in palliative care during one week
Secondary objectives:
* Tolerance of HNFC at short term (1h and 24h) and long term (7 days) after initiation of HNFC
* Efficiency of HNFC at short term
Primary outcome: duration of use of the HNFC during 7 days
Secondary outcome:
* Tolerance: noise of the system of HNFC, side effects of high flow (nasal dryness..)
* Efficiency: evaluation of dyspnea by Borg scale and measure of respiratory rate and saturation of oxygen one hour after initiation of HNFC
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
- Patient followed for respiratory failure with palliative care and :
- More than 18 years old
- Dyspnea related to a respiratory disease
- Hypoxemia requiring the introduction of more than 4 liters of oxygen for a sp02 > 90%
- Patient affiliated to a social security system
- Patient less than 18 years old
- Patient with guardianship, trusteeship
- No consent for participation at the study
- Project of curative care
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description High-flow nasal oxygen high-flow nasal cannula oxygen therapy (HNFC) -
- Primary Outcome Measures
Name Time Method Acceptability of HNFC in patients with dyspnea in palliative care during one week 7 days Duration of use of HNFC: nurses will set up the device to the patient who can withdraw it at any time. It will then be noted the stop time and recovery of the device for a week, which will know the time of use and acceptability. If the patient wishes to permanently stop the use of the device, the stop time will be raised.
- Secondary Outcome Measures
Name Time Method Efficiency of high-flow nasal oxygen in palliative care with Sp02 At short term: one hour after the initiation and at long term: 24h and seven days after the start Evaluation of Sp02 using transcutaneous oximeter
Efficiency of high-flow nasal oxygen in palliative care with respiratory rate At short term: one hour after the initiation and at long term: 24h and seven days after the start Evaluation of respiratory rate
Efficiency of high-flow nasal oxygen in palliative care with dyspnea At short term: one hour after the initiation and at long term: 24h and seven days after the start Evaluation of dyspnea with the Borg scale. The Borg scale is a scale containing 10 proposals ranging in increasing order of severity (from no gene at all to extremely embarrassed) that will allow the patient to grading his respiratory gene.
Trial Locations
- Locations (1)
Hospital LARREY, CHU Toulouse
🇫🇷Toulouse, France